home / stock / ubx / ubx news

UBX News and Press, Unity Biotechnology Inc. From 03/24/25

Stock Information
Company Name: Unity Biotechnology Inc.
Stock Symbol: UBX
Market: NASDAQ
Website: unitybiotechnology.com
Menu
UBX UBX Quote UBX Short UBX News UBX Articles UBX Message Board
Get UBX Alerts

News, Short Squeeze, Breakout and More Instantly...
UBX - UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial

2025-03-24 09:29:48 ET More on Unity Biotechnology Seeking Alpha’s Quant Rating on Unity Biotechnology Historical earnings data for Unity Biotechnology Financial information for Unity Biotechnology Read the full article on Seeking Alpha For fur...
UBX - UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidence interval), but did not meet statistical non-inferiority on the average of weeks 20 a...

UBX - UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025

SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a virtual investor event on Monday, March...

UBX - UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors

SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Yehia Hashad, M.D., executive vice president of research and develop...
UBX - Unity Biotechnology GAAP EPS of -$0.50 misses by $0.14

2025-03-07 16:35:12 ET More on Unity Biotechnology Seeking Alpha’s Quant Rating on Unity Biotechnology Historical earnings data for Unity Biotechnology Financial information for Unity Biotechnology Read the full article on Seeking Alpha For fur...

UBX - UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, ...

UBX - Unity Biotechnology Inc. (NASDAQ: UBX) Sees Notable Increase in Thursday Morning Market Activity

Unity Biotechnology, Inc. (NASDAQ: UBX) is one of today's top gainers. The company's shares have moved 29.19% on the day to $2.7. Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company...
UBX - Unity Biotechnology gets new chief medical officer

2025-01-06 08:42:47 ET More on Unity Biotechnology Unity Biotechnology GAAP EPS of -$0.38 beats by $0.02 Seeking Alpha’s Quant Rating on Unity Biotechnology Historical earnings data for Unity Biotechnology Financial information for Unity Biotechnology ...

UBX - UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer

SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today strengthened the executive leadership team with the appointment of Federico Grossi, M...

Previous 10 Next 10